RT Journal Article
SR Electronic
T1 Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.21.21260964
DO 10.1101/2021.07.21.21260964
A1 Yao Zhang
A1 Xiaohua Hao
A1 Ji Ma
A1 Mingming Wang
A1 Yanyan Li
A1 Yang Liu
A1 Dong Zhao
A1 Wen Zhang
A1 Chunming Li
A1 Li Yan
A1 Qing Zhu
A1 Fujie Zhang
YR 2021
UL http://medrxiv.org/content/early/2021/07/23/2021.07.21.21260964.abstract
AB Background BRII-196 and BRII-198 are two anti-SARS-CoV-2 monoclonal neutralizing antibodies with modified Fc region that extends half-life and are being developed as cocktail therapy for the treatment of COVID-19. Safety, tolerability, pharmacokinetics, and immunogenicity of BRII-196 and BRII-198 were investigated in healthy adults.Methods Single ascending doses of BRII-196 and BRII-198 were evaluated in parallel in the first-in-human, placebo-controlled phase 1 studies. A total of 32 healthy adults were randomized and received a single intravenous infusion of 750, 1500, and 3000 mg of BRII-196 (n=12), BRII-198 (n=12), or placebo (n=8) and were followed for 180 days.Results All infusions were well tolerated at infusion rates between 0.5 mL/min to 4 mL/min with no dose-limiting adverse events, deaths, serious adverse events, or any systemic or local infusion reactions. Most treatment-emergent adverse events were isolated asymptomatic laboratory abnormalities of Grade 1-2 in severity. Each mAb displayed pharmacokinetics expected of Fc-engineered human IgG1 with mean terminal half-lives of approximately 46 days and 76 days, respectively, with no evidence of significant anti-drug antibody development.Conclusions BRII-196 and BRII-198 were well-tolerated. Clinical results support further development as therapeutic or prophylactic options for SARS-CoV-2 infection.Clinical Trials Registration NCT04479631 and NCT04479644Competing Interest StatementY.Z., J.M., Y.L., Y.L., M.W., C.L., L.Y., and Q.Z. are employees of Brii Biosciences. Y.Z. and Q.Z. are employees of TSB Therapeutics. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.Clinical TrialNCT04479631/NCT04479644Funding StatementThese trials were sponsored by TSB Therapeutics, a subsidiary company of Brii Biosciences.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol, amendments, and informed-consent forms were reviewed and approved by Ethical Review Committee at the site. This study was conducted in accordance with the International Conference on Harmonisation Guidance for Good Clinical Practice guidelines and all applicable local regulatory requirements and laws. Participants provided written informed consent before any study-related procedures were performed.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current studies are available from the corresponding author on reasonable request.